Topaloğlu Topaloğlu

Dr. Topaloğlu Topaloğlu

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IGivo gokmen
ivo gokmen
ETEbru Taştekin
Ebru Taştekin
NDNazan Demir
Nazan Demir
EOErkan Ozcan
Erkan Ozcan
AAAkgül Akgül
Akgül Akgül
İÇİrfan Çiçin
İrfan Çiçin
The aim of our study was to evaluate the incidence of KRAS/NRAS and BRAF mutations, analyze molecular patterns, and investigate associations with clinical parameters of these mutations in CRC KRAS/NRAS and BRAF mutations analyzed by next-generation sequencing. The detection rates of these mutations and patients’ demographics were recorded and the relationship between them was evaluated using the chi-square test. KRAS mutation was detected in 332 of 694 patients, while the mutation rates in KRAS exons 2/3 and 4 were 39.6%/3.2% and 5%, respectively. The most common mutation pattern was KRAS G12D. Five atypical variants were detected: V14I in KRAS exon 2, A18D, Q22K and T50I in exon 3, and T148P in exon 4. NRAS mutation was detected in 29 (4.5%) patients. One atypical variant L80W was detected in NRAS exon 3. BRAF mutation was seen in 37 (5.3%) patients, with BRAFV600E (83.8%) being the most common mutation pattern. NRAS mutation was significantly more frequent in patients > 64 years of age, BRAF mutation in women, and NRAS/BRAF mutations in right colon tumors. Grouping BRAF mutations into BRAFV600E and BRAFnon-V600E and their analysis according to specific tumor localizations showed that all four BRAFnon-V600E mutations originated in the rectum. In our study, KRAS exon 2 and other RAS mutation rates were higher than in the literature, while the BRAF v.600E mutation rate was similar. NRAS and BRAF mutations were significantly more frequent in the right colon. BRAF mutation was more common in women and in the right colon.

8 December 2010 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
TTTopaloğlu Topaloğlu
Topaloğlu Topaloğlu
HKHakan Karagol
Hakan Karagol
FOFulya Ozpuyan
Fulya Ozpuyan
RCRusen Cosar
Rusen Cosar
İÇİrfan Çiçin
İrfan Çiçin
ZKZafer Kocak
Zafer Kocak

9 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
İBİbrahim Vedat Bayoğlu
İbrahim Vedat Bayoğlu
JHJavid Hüseynov
Javid Hüseynov
ATAlper Topal
Alper Topal
NSnadiye sever
nadiye sever
NANargiz Majidova Altuntash
Nargiz Majidova Altuntash
İÇİrfan Çiçin
İrfan Çiçin
Introduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting. Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan–Meier and Cox regression analysis. Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS. Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.

1 September 2013 in Hepatogastroenterology
Verified
Journal Article
Closed access
BEBulent Erdogan
Bulent Erdogan
ETEsma Turkmen
Esma Turkmen
TTTopaloğlu Topaloğlu
Topaloğlu Topaloğlu
OTOzgur Tanriverdi
Ozgur Tanriverdi
İÇİrfan Çiçin
İrfan Çiçin
To define the factors related with disease control and survival in patients with pancreaticobiliary adenocarcinoma treated with second-line therapy. We retropectively reviewed the data of 39 pancreaticobiliary adenocarcinoma patients treated with second-line chemotherapy between 2000 and 2012. Age, gender, origin of tumor, location of tumor, stage at diagnosis, Eastern Cooperative Oncology Group (ECOG) performance status, progression site, progression free survival (PFS) for first-line therapy, disease control at first-line therapy and chemotherapy protocols are analyzed for disease control rate, PFS and overall survival (OS). Disease control was recorded in 21 (53.8%) patients (20 stable disease, 1 partial response). Disease control rate was higher in patients with good performance status (p=0.03). Disease control at first-line therapy was not a predictor of disease control at second-line (p=0.6). Response to first-line therapy and other prognostic factors was not related with disease control. Progression free survival and OS was significantly longer in patients with good ECOG performance status (0-1) (p=0.01, p=0.006). Choice of chemotherapy (single agent or combination) and other factors did not have any impact on PFS and OS. In multivariate analysis; disease control was independent prognostic factor for both PFS and OS (p<0.001), (p<0.001). Disease control and performance status are two important prognostic factors. Chemotherapy regimen has no impact on disease control and survival. Salvage chemotherapy can be considered for patients with good performance status whether they are resistant to first-line therapy or not.

16 January 2013 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
TTTopaloğlu Topaloğlu
Topaloğlu Topaloğlu
AAAysun Aybatlı
Aysun Aybatlı
PKPetek Balkanlı Kaplan
Petek Balkanlı Kaplan
İÇİrfan Çiçin
İrfan Çiçin
NSNecdet Sut
Necdet Sut
FVFusun Varol
Fusun Varol

9 November 2016 in Bosnian Journal of Basic Medical Sciences
Verified
Journal Article
Open access
PDF file
BEBülent Erdoğan
Bülent Erdoğan
HKHilmi Kodaz
Hilmi Kodaz
SKSenem Karabulut
Senem Karabulut
ACAhmet Cinkaya
Ahmet Cinkaya
HTHilmi Tozkir
Hilmi Tozkir
ICIrfan Cicin
Irfan Cicin
Lung cancer in smokers and non-smokers demonstrates distinct genetic profiles, and cigarette smoking affects epidermal growth factor receptor (EGFR) function and causes secondary EGFR tyrosine kinase resistance. We evaluated the effect of active smoking in patients with metastatic lung adenocarcinoma. A total of 132 metastatic lung adenocarcinoma patients, diagnosed between 2008 and 2013, with known EGFR mutation status, were evaluated retrospectively. Among these patients, 40 had an activating EGFR mutation. Patients who continued smoking during the treatment were defined as active smokers. Former smokers and never smokers were together defined as non-smokers. The outcomes of the treatment in relation to the EGFR mutation and smoking status were evaluated. The median follow-up time was 10.5 months. The overall response rate for the first-line therapy was significantly higher among the EGFR-mutant patients (p = 0.01), however, smoking status had no impact on the response rate (p = 0.1). The EGFR-mutant active smokers progressed earlier than the non-smokers (p < 0.01). The overall survival (OS) of the non-smokers and patients treated with erlotinib was significantly longer (p = 0.02 and p = 0.01, respectively). Smoking status did not affect the OS in EGFR wild type tumors (p = 0.49) but EGFR-mutant non-smokers had a longer OS than the active smokers (p = 0.01).The active smokers treated with erlotinib had poorer survival than the non-smokers (p = 0.03). Multivariate analysis of EGFR-mutant patients showed that erlotinib treatment at any line and non-smoking were independent prognostic factors for the OS (p = 0.04 and p = 0.01, respectively). Smoking during treatment is a negative prognostic factor in metastatic lung adenocarcinoma with an EGFR mutation.